CMES6 The Effective Use of Insulin in Type 2 Diabetes: A Focus on Treatment Advances

Program: CMES Ancillary Events
Clinical Session
Friday, April 1, 2016: 6:30 PM-9:30 PM
Grand Ballroom (The Westin)
Supported by an educational grant from sanofi-aventis U.S. Inc.

Registration is required for this session:

Learning Objectives:

Upon completing this activity, learners will be better able to:

  • Analyze the role of insulin therapy for patients with T2DM
  • Discuss newly available and merging insulin therapies and how they compare with older agents, including their clinical utility
  • Identify strategies to overcome patient- and provider-derived barriers that may delay the initiation or escalation of insulin therapy, including how newer agents may address these barriers
  • Develop individualized diabetes management plans that effectively use insulin alone or in combination with other therapies, based on patient-specific needs
7:00 PM

John (Jack) L Leahy, MD, Univ of VT Coll of Med, Colchester, VT
Disclosures:
JLL: Advisory Group Member, Novo Nordisk, Advisory Group Member, Merck & Co., Advisory Group Member, Sanofi, Advisory Group Member, Johnson &Johnson.
7:15 PM

Lawrence Blonde, MD, FACP, FACE, Frank Riddick Diabetes Institute, Department of Endocrinology, Ochsner Medical Center, New Orleans, LA
Disclosure Not Provided: LB
7:50 PM

Marie E. McDonnell, MD, Medicine/Endocrinology, Brigham and Women's Hospital, Boston, MA
Nothing to Disclose: MEM
8:25 PM

Janet B McGill, MD, Campus Box 8127, Washington University School of Medicine, Saint Louis, MO
Disclosure Not Provided: JBM
9:00 PM

John (Jack) L Leahy, MD, Univ of VT Coll of Med, Colchester, VT
Disclosures:
JLL: Advisory Group Member, Novo Nordisk, Advisory Group Member, Merck & Co., Advisory Group Member, Sanofi, Advisory Group Member, Johnson &Johnson.
See more of: CMES Ancillary Events